Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05493111 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
A Phase 3 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
NCT05493111 is a Phase 3 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 275 participants.
The verdict
NCT05493111, a Phase 3 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.
Interventions
- DRUG 0.003% AR-15512 ophthalmic solution
- DRUG AR-15512 vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05493111
The ClinicalTrials.gov registry entry for NCT05493111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.003% AR-15512 ophthalmic solution is the first listed.
NCT05493111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05493111 about?
NCT05493111 is a clinical study titled "A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512". The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.
What is the current status of trial NCT05493111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2022-11-01. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05493111?
The interventions under investigation include: 0.003% AR-15512 ophthalmic solution (DRUG), AR-15512 vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05493111?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.